Aurinia Pharmaceuticals
AUPH
14.70
-0.19
-1.28%
Aurinia Pharmaceuticals
US · AUPH
#2749 by market cap
Listed 1970
14.70
-0.19
-1.28%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
RBC Capital Maintains Aurinia Pharmaceuticals(AUPH.US) With Hold Rating, Maintains Target Price $15Market Newswire · 2026/2/27
-
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17Market Newswire · 2026/8/20
-
Rating change
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Neumora Therapeutics, Inc. (NMRA) and Aurinia Pharmaceuticals (AUPH)TipRanks · 2026/3/31
-
Rating change
Leerink Partners Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $10Market Newswire · 2025/7/2
-
Rating change
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $11Market Newswire · 2025/8/1
-
Bloom Burton Upgrades Aurinia Pharmaceuticals(AUPH.US) to Buy Rating, Raises Target Price to $21Market Newswire · 2026/8/20
-
Rating change
RBC Capital Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Cuts Target Price to $8Market Newswire · 2025/2/28
-
Rating change
Jefferies Upgrades Aurinia Pharmaceuticals(AUPH.US) to Buy Rating, Raises Target Price to $21Market Newswire · 2025/11/7
-
Rating change
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $17Market Newswire · 2025/11/5
-
Rating change
Leerink Partners Downgrades Aurinia Pharmaceuticals(AUPH.US) to Hold Rating, Raises Target Price to $16Market Newswire · 2025/12/3
-
Rating change
H.C. Wainwright Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17Market Newswire · 2026/2/27
-
Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q3 EPS $0.23, Vs. FactSet Est of $0.22MT Newswires · 2026/10/30
-
Rating change
TR | OpenAI - 4o Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $13Market Newswire · 2025/8/6
-
Rating change
RBC Capital Downgrades Aurinia Pharmaceuticals(AUPH.US) to Hold Rating, Raises Target Price to $15Market Newswire · 2025/11/5
-
Bloom Burton Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $21Market Newswire · 2026/11/3
-
Rating change
Bloom Burton Maintains Aurinia Pharmaceuticals(AUPH.US) With Hold Rating, Maintains Target Price $15Market Newswire · 2026/3/31
-
Rating change
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Aurinia Pharmaceuticals (AUPH) and RegenXBio (RGNX)TipRanks · 2025/5/13
-
Aurinia Pharmaceuticals(AUPH.US) 10% Shareholder Buys US$12.46 Million in Common StockMarket Newswire · 2026/6/3
-
Rating change
Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), MAIA Biotechnology, Inc. (MAIA) and CG Oncology, Inc. (CGON)TipRanks · 2026/3/2
-
Rating change
H.C. Wainwright Initiates Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Announces Target Price $17Market Newswire · 2025/7/30
-
Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q3 Revenue $83.7M, Vs. FactSet Est of $83.6MMT Newswires · 2026/10/30
-
Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q1 EPS $0.25, Vs. FactSet Est of $0.20MT Newswires · 2026/5/7
-
Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q2 Revenue $83.2M, Vs. FactSet Est of $80.4MMT Newswires · 2026/8/6
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.
Aurinia Pharmaceuticals discussion 0 comments